Following the successful completion of the USFDA audit and receiving approval on 16th May, 2025, we successfully shipped 8 FCL shipments and fulfilled the received order. Despite ongoing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Veerhealth Care received a fresh order from its US-based customer for manufacture and supply of oral care products, valued at Rs. 0.20 Crores, to be executed within 30 days. The order follows the company's successful USFDA audit and approval received on 16th May 2025, after which it shipped 8 full container loads (FCL) and fulfilled a previous order. The new order comes despite ongoing tariff uncertainties, indicating continued customer trust. The customer's identity is withheld under a non-disclosure agreement, and the transaction is not a related-party deal.
The USFDA approval is a key positive milestone that strengthens Veerhealth Care's export credentials, but the fresh order value of Rs. 0.20 Cr is very small and unlikely to materially move the needle on revenue or stock price in the near term. The development signals export potential rather than an immediate earnings catalyst.